Depletion of alloreactive T cells via CD69: Implications on antiviral, antileukemic and immunoregulatory T lymphocytes

Bone Marrow Transplantation

Volumn 37, Issue 3, 2006, Pages 297-305

  Hartwig, U F ^a   Nonn, M ^a   Khan, S ^a   Meyer, R G ^a   Huber, C ^a   Herr, W ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Allogeneic hematopoietic stem cell transplantation; CD69; GVHD; GVL; T cell depletion

Indexed keywords

CD69 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; GAMMA INTERFERON; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; ANTIGEN EXPRESSION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL SEPARATION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; NEPHROBLASTOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STATISTICAL SIGNIFICANCE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CARRIER PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA-BINDING PROTEINS; EPSTEIN-BARR VIRUS INFECTIONS; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; NUCLEAR PROTEINS; RECEPTORS, INTERLEUKIN-2; TRANSPLANTATION, HOMOLOGOUS;

EID: 33645317646     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705238     Document Type: Article

References (41)

1. Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: Potential implications for marrow transplantation in humans. J Exp Med 1993; 178: 703-712.
2. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 1992; 257: 238-241.
3. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
4. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
5. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
6. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs-host disease. Biol Blood Marrow Transplant 1999; 5: 347-356.
7. Hartwig UF, Robbers M, Wickenhauser C, Huber C. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood 2002; 99: 3041-3049.
8. Yang YG, Qi J, Wang MG, Sykes M. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood 2002; 99: 4207-4215.
9. Slavin S, Morecki S, Weiss L, Or R. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Crit Rev Oncol Hematol 2003; 46: 139-163.
10. Gao L, Yang TH, Tourdot S, Sadovnikova E, Hasserjian R, Stauss HJ. Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease. Blood 1999; 94: 2999-3006.
11. Barrett AJ, Malkovska V. Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 1996; 93: 754-761.
12. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T-cells by photodynamic cell purging process. Blood 2002; 99: 3083-3088.
13. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.
14. Mavroudis DA, Dermime S, Molldrem J, Jiang YZ, Raptis A, van Rhee F et al. Specific depletion of alloreactive T-cells in HLA-identical siblings: A method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol 1998; 101: 565-570.
15. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: A phase 1/2 study. Lancet 2002; 360: 130-137.
16. Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED et al. Selective depletion of donor alloreactive T-cells without loss of antiviral or antileukemic responses. Blood 2003; 102: 2292-2299.
17. Garderet L, Snell V, Przepiorka D, Schenk T, Lu JG, Marini F et al. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation 1999; 67: 124-130.
18. Koh MB, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from haematopoietic stem cell grafts: Graft engineering for GVHD prophylaxis. Bone Marrow Transplant 1999; 23: 1071-1079.
19. Fehse B, Frerk O, Goldmann M, Bulduk M, Zander AR. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Hematol 2000; 109: 644-651.
20. Martins SL, St John LS, Champlin RE, Wieder ED, McMannis J, Molldrem JJ et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 2004; 104: 3429-3436.
21. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+) CD25(+) regulatory T-cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.
22. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985; 21: 235-246.
23. Britten CM, Meyer RG, Kreer T, Drexler I, Wolfel T, Herr W. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods 2002; 259: 95-110.
24. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T-cell immunity against cancer. Clin Cancer Res 2003; 9: 4296-4303.
25. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198-2203.
26. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S et al. CD4+ CD25+ regulatory T-cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150.
27. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD et al. Human CD4(+) CD25(+) cells: A naturally occurring population of regulatory T-cells. Blood 2001; 98: 2736-2744.
28. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T-cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193: 1295-1302.
29. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
30. Gribben JG, Guinan EC, Boussiotis VA, Ke XY, Linsley L, Sieff C et al. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: A method to ameliorate graft-versus-host disease and extend the donor pool. Blood 1996; 87: 4887-4893.
31. Craston R, Koh M, Mc Dermott A, Ray N, Prentice HG, Lowdell MW. Temporal dynamics of CD69 expression on lymphoid cells. J Immunol Methods 1997; 209: 37-45.
32. Riddell SR, Greenberg PD. T-cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev Med Virol 1997; 7: 181-192.
33. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767-776.
34. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405-1412.
35. Dunn HS, Douglas JH, Ghansekar SA, Stepick-Biek P, Lewis DB, Maecker HT. Dynamics of CD4 and CD8 T-cell responses to cytomegalovirus in healthy human donors. J Infect Dis 2002; 186: 15-22.
36. + T-cells that are specific for certain viral epitopes. Arthritis Res 2000; 2: 154-164.
37. Wood KJ, Sakaguchi S. Regulatory T-cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210.
38. Shevach EM. Certified professionals: CD4(+) CD25(+) suppressor T-cells. J Exp Med 2001; 193: 41-46.
39. Davies JK, Koh MB, Lowdell M. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Biol Blood Marrow Transplant 2004; 10: 259-268.
40. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T-cells. J Immunol Methods 1990; 128: 189-201.
41. Rauser G, Einsele H, Sinzger C, Wernet D, Kuntz G, Assenmacher M et al. Rapid generation of combined CMV specific CD4 + and CD8 + cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004; 103: 3565-3572.